Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Chava Perry(Tel Aviv University), Irit Avivi(Tel Aviv Sourasky Medical Center), Gabi Shefer(Tel Aviv Sourasky Medical Center), M. Morales(Tel Aviv Sourasky Medical Center), Ofrat Beyar‐Katz(Rambam Health Care Campus), Yaara Tabib(Tel Aviv Sourasky Medical Center), Yaël C. Cohen(Tel Aviv University), Miriam Neaman(Tel Aviv University), Roy Vitkon(Tel Aviv University), Y. Herishanu(Tel Aviv University), Adi Aharon(Tel Aviv University), R. Balaban(Tel Aviv Sourasky Medical Center), Efrat Luttwak(Tel Aviv University), M Levin(Tel Aviv Sourasky Medical Center), Noam Benyamini(Tel Aviv University)
Blood Advances
August 13, 2021
10.1182/bloodadvances.2021005094
Cited by 170

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164
A randomized study comparing yttrium‐90 ibritumomab tiuxetan (Zevalin) and high‐dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
|Cancer|2012|108
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
|Cancer Research|2018|103
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
|Leukemia|2019|69